



## **Synosia Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson's Disease**

**Basel, Switzerland, February 1, 2010** – Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson's disease.

The Phase IIa trial was a randomised, double-blind, placebo-controlled, cross-over study in 24 Parkinson's patients using doses up to 120mg/day for one week. The effects of SYN-115 as an add-on therapy to a stable dose of levodopa was assessed using a number of techniques, including functional Magnetic Resonance Imaging (fMRI), clinical ratings such as the Unified Parkinson's Disease Rating Scale and various cognitive tests.

The data from fMRI using arterial spin labelling showed that SYN-115 produced statistically significant, dose-related changes in blood flow in regions of the brain known to be relevant to Parkinson's. Activity in these regions is known to be modulated by established Parkinson's treatments such as dopamine agonists and levodopa.

Further positive results on multiple clinical endpoints of motor and non-motor symptoms of Parkinson's disease will be announced in the coming months.

Principal investigator Dr Kevin Black, Associate Professor of Psychiatry, Neurology, Radiology and Neurobiology at the Washington University School of Medicine in St. Louis, Missouri, said: "These encouraging results suggest that SYN-115 is able to cross the blood-brain barrier and have an effect that could be beneficial to patients with Parkinson's."

"The innovative, imaging techniques used have given us a great deal of information to help plan future clinical trials of SYN-115," said Dr Steve Bandak, Synosia's Chief Medical Officer. "We have successfully established that SYN115 is getting into the brain, changing the activity of relevant regions of the brain, and we now have a better understanding of the doses that are likely to be therapeutically useful. Those were our objectives in undertaking the study."

**About SYN-115**

SYN-115 is a potent and selective third-generation inhibitor of the A2a receptor and is being developed by Synosia as a potential add-on therapy to a stable dose of levodopa, the current gold standard of treatment in Parkinson's, or as a monotherapy.

Rights to SYN-115 were obtained by Synosia from Roche (SIX: RO, ROG; OTCQX: RHHBY) in 2007 for development in selected indications of the central nervous system.

### **About Parkinson's Disease**

Parkinson's disease is the second most common neurodegenerative disorder, after Alzheimer's disease. It affects about one per cent of people aged 65-69 years, rising to up to three per cent of people aged 80 years and older.<sup>1</sup>

### **About Synosia**

Synosia Therapeutics is a privately owned company, which develops and intends to commercialise innovative, first or best-in-class products for unmet medical needs in neurology and psychiatry. Synosia utilises cutting-edge technologies and creative clinical study designs to de-risk its compounds before moving into larger, more extensive Phase II and Phase III programmes.

Synosia has five clinical-stage compounds in development for neurological and psychiatric diseases that have high unmet medical need, including Parkinson's and Alzheimer's disease. Synosia is headquartered in Basel, Switzerland. For more information visit [www.synosia.com](http://www.synosia.com)

### **References**

1. Guttmacher et al. Alzheimer's Disease and Parkinson's Disease. New England Journal of Medicine (2003); 348; 1356-64

### **Disclaimer**

This communication, and oral statements made with respect to information contained in this communication, expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our regulatory filings, enrolment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potential", "could" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the respective regulatory agencies refuse approval of our applications, the outcome of any discussions with such regulatory agencies and

unexpected delays in preparation of materials for submission to such respective regulatory agencies as a part of our filings.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.